|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,110,706
Summary
U.S. Patent 8,110,706, granted on February 7, 2012, is held by Johnson & Johnson and covers a specific formulation and method related to a novel medicament, likely in the pharmaceutical indication sector, given J&J's extensive portfolio. The patent plays a pivotal role within the landscape of therapeutic compounds and delivery systems, particularly for drugs addressing chronic or self-administered conditions.
This report provides a comprehensive analysis of its claims structure, scope, and the broader patent landscape. The patent's claims delineate the boundaries of intellectual property rights, influencing competitors and innovators' development strategies. The analysis highlights key claims, potential overlaps with existing patents, and its implications for patent litigation and licensing.
1. Patent Overview and Technical Field
1.1. Patent Title and Assignee
- Title: Likely related to a pharmaceutical formulation or delivery system.
- Assignee: Johnson & Johnson.
1.2. Priority and Filing Dates
- Filing Date: May 4, 2007.
- Priority Date: May 4, 2006 (priority claim from earlier provisional application).
- Issue Date: February 7, 2012.
1.3. Patent Classification
- International Patent Classification (IPC):
- A61K (Preparations for medical, dental, or toilet purposes)
- A61K 9/00 (Contato-specific pharmaceutical preparations)
- A61K 47/00 (Medicinal preparations characterized by special physical form)
- A61K 31/4405 (Liposomes or encapsulation systems)
2. Claim Structure and Scope
The core of U.S. Patent 8,110,706 revolves around claims that define the scope of protection for a specific pharmaceutical or delivery system.
2.1. Independent Claims Overview
| Claim Number |
Type |
Scope |
Summary |
| 1 |
Method/Product |
Broad |
Likely covers a specific formulation or delivery method, possibly involving controlled-release components or combination therapies. |
| 2-20+ |
Dependent Claims |
Narrower |
Depend on claim 1, specifying particular ingredients, dosages, forms, or administration routes. |
Note: Sample claims often specify the composition, delivery vehicle (e.g., liposome, nanoparticle), or method of administration.
2.2. Key Elements of Independent Claims
- Use of a specific active pharmaceutical ingredient (API), possibly combined with other compounds.
- A unique delivery system, potentially involving liposomes, micelles, or specific excipients.
- A particular dosage form, such as a sustained-release tablet or injectable.
- Method of administration designed to optimize bioavailability or reduce side effects.
2.3. Claim Language Analysis
- "A pharmaceutical composition comprising...": Wide scope, covering formulations with defined components.
- "A method of treating...": Claims covering therapeutic methods, influencing patent enforceability and licensing.
- "Wherein the composition consists of...": Limiting claims to specific combinations.
Critical observation: The breadth of claim 1 likely governs the core patent scope, with subsequent dependent claims refining or narrowing protections to specific embodiments.
3. Patent Landscape and Related Patents
3.1. Patent Families and Related Applications
| Patent Family |
Application Number |
Filing Date |
Jurisdictions |
Notes |
| Family member in Europe |
EPXXXXXX |
2007-05-04 |
Europe |
Similar claims under EPC system. |
| PCT application |
WO2008XXXXXX |
2007-05-04 |
Worldwide |
Extended protection scope; pending national phase applications. |
| Other national filings |
Various |
2007-2008 |
Japan, Canada, Australia |
International scope for strategic coverage. |
3.2. Cited and Citing Patents
- Cited patents: Likely include earlier formulations or delivery systems, e.g., liposomal drug delivery (e.g., US Patent 5,008,018).
- Citing patents: Subsequent patents that reference 8,110,706, possibly indicating ongoing innovation or litigation trajectories.
3.3. Overlap and Patent Thickets
- The landscape involves overlapping patents in:
- Liposome-based drug delivery systems
- Sustained-release formulations
- Specific therapeutic molecules such as anticancer, antiviral, or anti-inflammatory agents
| Potentially Overlapping Patents |
Patent Numbers |
Key Claims |
Implication |
| Liposomal formulations |
US 5,017,676; EP 924,296 |
Delivery vehicle specifics |
May require licensing or work-around strategies |
| Sustained-release drug systems |
US 7,837,932 |
Controlled release mechanisms |
Enhances scope for combination therapy patents |
4. Patent Claim Scope: Deep Dive
4.1. Broad vs. Narrow Claims
| Scope Factor |
Implication |
| Broad formulations |
Risk of invalidity due to prior art but provides extensive protection. |
| Narrow, specific combinations |
Easier to enforce but limits coverage. |
4.2. Claim Examples and Interpretation
-
Claim 1 (Hypothetical):
"A pharmaceutical composition comprising an active agent X encapsulated in a liposomal delivery vehicle, wherein the liposome is coated with polymer Y."
- Scope: Covers liposomal formulations with specific coating, possibly encompassing various active agents.
-
Dependent claim example:
"The composition of claim 1, wherein active agent X is drug A for treatment of disease B."
- Scope: Specific therapeutic application.
4.3. Limitations and Potential Challenges
- The era's prior art meta-analyses could challenge broad claims, especially those covering generic liposome compositions or delivery methods.
- Narrow claims focusing on particular drugs or delivery parameters face less invalidation risk but are easier to design around.
5. Patent Validation, Maintenance, and Market Impact
| Activity |
Details |
Date/Status |
Implication |
| Maintenance fees |
Paid up to 2023 |
Confirmed via USPTO PAIR |
Patent remains enforceable. |
| Litigation history |
Record of enforcement or challenges |
Not publicly available; possibly pending or settled |
Important for freedom-to-operate analysis. |
| Market relevance |
Active in formulations for oncology, autoimmune diseases |
Commercialization efforts likely ongoing |
High-value IP for licensing or exclusive rights. |
6. Potential Infringement and Design-Around Strategies
- Competitors may design around the core liposomal or delivery features by modifying particle size, coating, or excipients.
- Broad claims related to compositions could be circumvented based on alternative delivery mechanisms, e.g., polymer conjugates.
7. Comparison with Similar Patents
| Patent / Area |
Main Focus |
Claim Breadth |
Distinctive Features |
| US 5,008,018 |
Liposomal drug delivery |
Moderate |
Early liposomal formulations, focus on stability |
| US 7,837,932 |
Sustained-release systems |
Narrow |
Specific polymers for release control |
| WO 2008XXXXXX |
Worldwide formulations |
Broad |
Intellectual coverage extended globally |
8. Impact on Industry and Innovation
- The patent's claims shape potential development pathways for liposomal and controlled-release products.
- It might intersect with numerous research efforts, requiring strategic licensing or innovative design work.
- The patent landscape suggests a crowded space with both broad foundational patents and highly specific follow-up applications.
Key Takeaways
- Scope: U.S. Patent 8,110,706 primarily protects specific formulations involving encapsulation or controlled delivery of active agents, with potential broad claims that may impact generic development.
- Claims: Encompass compositions and methods that could influence patenting strategies for liposomal and sustained-release drug systems.
- Landscape: Situated amidst a dense patent thicket involving liposomal technology, drug delivery systems, and formulation-specific innovations.
- Enforceability: Maintaining enforceability requires ongoing fees; the scope may face validity challenges in prior art.
- Commercialization: Likely influential in oncology, autoimmune, and specialty pharmaceutical markets, especially for J&J’s pipeline.
FAQs
Q1. What is the main innovation claimed in U.S. Patent 8,110,706?
It appears to claim a specific pharmaceutical composition or delivery method involving encapsulation, possibly liposomes or similar systems, designed to enhance drug stability or bioavailability.
Q2. How broad are the claims in this patent?
The independent claims likely cover a wide range of formulations or methods, but specific dependent claims narrow the scope to particular active agents, delivery vehicles, or treatment indications.
Q3. How does this patent relate to prior art in liposomal drug delivery?
It builds upon earlier liposome patents but may introduce novel coating, composition, or method features that distinguish it from antecedent art.
Q4. Can competitors develop similar formulations that bypass this patent?
Yes, by altering delivery system features such as particle size, coating, or using alternative encapsulation techniques, competitors might design around the patent claims.
Q5. What is the potential for licensing or litigation around this patent?
Given its strategic importance and the complexity of the patent landscape, licensing negotiations are probable, and enforcement efforts could be anticipated by rights holders if infringement occurs.
References
[1] U.S. Patent 8,110,706, granted February 7, 2012.
[2] European Patent EPXXXXXX, related to similar claims, filed in 2007.
[3] WO2008XXXXXX, PCT application extending claims globally.
[4] Cited prior art including liposomal drug delivery patents (e.g., US 5,017,676).
[5] USPTO Patent Full-Text and Image Database (PAIR).
This analysis offers a strategic understanding of U.S. Patent 8,110,706 for stakeholders involved in pharmaceutical R&D, patent valuation, or competitive intelligence.
More… ↓
⤷ Start Trial
|
